ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.60
0.71%
US Tech 100
19,636.04
0.55%
S&P 500
5,770.20
0.55%
US Dollar vs CAD
1.43715
0.00%
Bitcoin
85,991.80
-0.19%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. NextCure Inc (NXTC)

  7. NextCure Inc (NXTC) News

NXTC

NextCure (NXTC)

NextCure Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NXTC
DateTimeSourceHeadlineSymbolCompany
03/06/20253:05PMGlobeNewswire Inc.NextCure Provides Business Update and Reports Full Year 2024 Financial ResultsNASDAQ:NXTCNextCure Inc
02/14/202512:40PMEdgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:NXTCNextCure Inc
02/06/20253:16PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
02/03/20255:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
02/03/20255:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
02/03/20253:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NXTCNextCure Inc
01/10/20257:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NXTCNextCure Inc
01/10/20257:05AMGlobeNewswire Inc.NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple CancersNASDAQ:NXTCNextCure Inc
12/10/20247:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NXTCNextCure Inc
12/10/20247:05AMGlobeNewswire Inc.NextCure Announces Acceptance of IND Application for LNCB74NASDAQ:NXTCNextCure Inc
12/05/20246:11AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NXTCNextCure Inc
11/26/20246:00AMGlobeNewswire Inc.NextCure to Participate in the 36th Annual Piper Sandler Healthcare ConferenceNASDAQ:NXTCNextCure Inc
11/19/20247:05AMGlobeNewswire Inc.Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis ImperfectaNASDAQ:NXTCNextCure Inc
11/14/20245:59PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:NXTCNextCure Inc
11/07/20243:15PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NXTCNextCure Inc
11/07/20243:05PMGlobeNewswire Inc.NextCure Provides Business Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:NXTCNextCure Inc
11/05/20243:05PMGlobeNewswire Inc.NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual MeetingNASDAQ:NXTCNextCure Inc
10/04/20248:05AMGlobeNewswire Inc.NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual MeetingNASDAQ:NXTCNextCure Inc
09/16/20247:05AMGlobeNewswire Inc.NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024NASDAQ:NXTCNextCure Inc
08/01/20243:15PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NXTCNextCure Inc
08/01/20243:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NXTCNextCure Inc
08/01/20243:05PMGlobeNewswire Inc.NextCure Provides Business Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:NXTCNextCure Inc
06/20/20243:10PMGlobeNewswire Inc.NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceNASDAQ:NXTCNextCure Inc
06/18/20243:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NXTCNextCure Inc
05/30/20243:05PMGlobeNewswire Inc.NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024NASDAQ:NXTCNextCure Inc
05/02/20243:05PMGlobeNewswire Inc.NextCure Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:NXTCNextCure Inc
04/24/20243:05PMGlobeNewswire Inc.NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024NASDAQ:NXTCNextCure Inc
04/08/20246:00AMGlobeNewswire Inc.NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024NASDAQ:NXTCNextCure Inc
04/04/20246:05AMGlobeNewswire Inc.NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory BoardNASDAQ:NXTCNextCure Inc
04/02/20246:00AMGlobeNewswire Inc.NextCure to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:NXTCNextCure Inc
 Showing the most relevant articles for your search:NASDAQ:NXTC

Your Recent History

NYSE
FXLV
F45 Training
LSE
05GL
Nat.gas.t 7e%
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads